For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications ; The study was ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

Medicare seeks public comments as the agency plans to list up to 15 additional drugs selected for the third round of pricing ...